Researchers from China published a report on the results of the third phase of clinical trials of the new neuroprotectant lobemisal, intended for the treatment of acute ischemic stroke.
It was found that when this drug was administered intravenously within 48 hours after the onset of symptoms, lobemisal significantly increased the probability of achieving full functional recovery in patients.
This trial progress report was published in the scientific journal JAMA: The Journal of the American Medical Association.